XML 42 R23.htm IDEA: XBRL DOCUMENT
v3.24.0.1

Summary of Significant Accounting Policies (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2023
Accounting Policies [Abstract] |
Summary of Fair Value Measurement Financial Assets | Financial assets measured at fair value on a recurring basis were as follows (in thousands):
| Fair Value Measurement at December 31, 2023
| Total |  | Level 1 |  | Level 2
Assets: |  |  |  |  |
Money market funds | $ | 91,665 |  |  | $ | 91,665 |  |  | $ | — |
U.S Treasury securities | 31,179 |  |  | — |  |  | 31,179 |
Government-sponsored enterprises | 45,043 |  |  | — |  |  | 45,043 |
Corporate debt securities | 52,627 |  |  | — |  |  | 52,627 |
Total assets measured at fair value (a) | $ | 220,514 |  |  | $ | 91,665 |  |  | $ | 128,849 |
| Fair Value Measurement at December 31, 2022
| Total |  | Level 1 |  | Level 2
Assets: |  |  |  |  |
Money market funds | $ | 41,564 |  |  | $ | 41,564 |  |  | $ | — |
Government-sponsored enterprise | 32,811 |  |  | — |  |  | 32,811 |
Corporate debt securities | 17,626 |  |  | — |  |  | 17,626 |
Total assets measured at fair value (b) | $ | 92,001 |  |  | $ | 41,564 |  |  | $ | 50,437 |
(a) Total assets measured at fair value at December 31, 2023 includes approximately $91.7 million reported as cash and cash equivalents and $128.8 million reported as marketable securities on the balance sheet. (b) Total assets measured at fair value at December 31, 2022 includes approximately $46.5 million reported as cash and cash equivalents and $45.5 million reported as marketable securities on the balance sheet.
Summary of Percentage of Customer Concentration | The following table includes those counterparties that represent more than 10% of total revenue earned in the periods indicated:
| Year Ended December 31,
| 2023 |  | 2022 |  | 2021
Incyte | 53% |  | 26% |  | 31%
McKesson Plasma & Biologics and McKesson Specialty Care Distribution LLC (McKesson) | 12% |  | * |  | *
ASD Healthcare and Oncology Supply (ASD) | 10% |  | * |  | *
Provention | 10% |  | 43% |  | *
Zai Lab Limited (Zai Lab) | * |  | 15% |  | 30%
I-Mab Biopharma (I-Mab) | * |  | * |  | 16%
* Amount is less than 10% for the period indicated. The following table includes those counterparties that represent more than 10% of accounts receivable at the date indicated:
| December 31,
| 2023 |  | 2022
Incyte | 25% |  | *
Cardinal Health, Inc | 18% |  | *
McKesson | 16% |  | *
ASD | 15% |  | *
Zai Lab | 12% |  | *
Provention | * |  | 84%
* Balance is less than 10% as of the date indicated.
Estimated Useful Lives | Depreciation and amortization are computed using the straight-line method over the following estimated useful lives:
Computer equipment | 3 years
Software | 3 years
Furniture | 10 years
Laboratory and office equipment | 5 years
Leasehold improvements | Shorter of lease term or useful life
Schedule of Stock Options and RSUs Excluded from the Calculation of Net Loss Per Share | The following table presents the number of stock options and RSUs that were excluded from the calculation of net loss per share:
| Year Ended December 31,
| 2023 |  | 2022 |  | 2021
Stock options and RSUs | 13,129,251 |  | 10,514,013 |  | 8,395,421

X
- Definition Property plant and equipment estimated useful life. + References No definition available. + Details
Name: | mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock
Namespace Prefix: | mgnx_
Data Type: | dtr-types1:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_AccountingPoliciesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2C -SubTopic 10 -Topic 820 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2C Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2 + Details
Name: | us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1 + Details
Name: | us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-16 Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-21 + Details
Name: | us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration